TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human
| ¥5800 | |
| Z04634-100 | |
|
|
|
|
|
|
|
|
|
| ¥5800 | |
| Z04634-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 19.4 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Human Trail at 5 μg/ml(100 μl/well) on the plate. Dose response curve for TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human, His Tag with the EC50 of 0.14ug/ml determined by ELISA. »
The purity of TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%. »
TRAIL R4/TNFRSF10D[Biotin], His & Avi, Human, His-Avi Tag immobilized on CM5 Chip can bind Human TRAIL, No Tag with an affinity constant of 0.135 nM as determined in SPR assay (Biacore T200). »
| Target Background | TNF-related apoptosis inducing ligand (TRAIL) is a potential antitumor protein known for its ability to selectively eliminate various types of tumor cells without exerting toxic effects in normal cells and tissues. TRAIL-R2/DR5 as well as TRAIL-R3/DcR1 and TRAIL-R4/DcR2 were significantly higher expressed in advanced tumour stages. |
| Synonyms | CD264; RSF10D; TRAILR4; DCR2; TRUNDD; TNFRSF10D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.